Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2002 Jan;43(1):121-6.

Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Author information

1
Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA.

Abstract

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas. In general, their prognosis is poor, and specific therapy is not well defined. We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK). This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.

PMID:
11908715
DOI:
10.1080/10428190210183
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center